The gamma interferon gene knockout mouse: A highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum

Journal of Clinical Microbiology

Volumn 36, Issue 9, 1998, Pages 2503-2508

  Griffiths, Jeffrey K ^a,b,c   Theodos, Cynthia ^a   Paris, Melissa ^a   Tzipori, Saul ^a,c  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NITAZOXANIDE; PAROMOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CAUSE OF DEATH; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DISEASE CONTROL; DOSE RESPONSE; GENE EXPRESSION REGULATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OOCYST; PATHOGENESIS; PRIORITY JOURNAL; SCID MOUSE; WASTING SYNDROME; WEIGHT REDUCTION;

ANIMALIA; CRYPTOSPORIDIUM PARVUM; MAMMALIA; PROTOZOA; RODENTIA;

EID: 0031826089     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.9.2503-2508.1998     Document Type: Article

References (22)

1. Blagburn, B. L., and R. Soave. 1997. Prophylaxis and chemotherapy: human and animal, p. 111-128. In R. Fayer (ed.), Cryptosporidium and cryptosporidiosis - 1997. CRC Press, Boca Raton, Fla.
2. Brasseur, P., D. Lemeteil, and J. J. Ballet. 1988. Rat model for human cryptosporidiosis. J. Clin. Microbiol. 26:1037-1039.
3. Current, W. L. 1990. Techniques and laboratory maintenance of Cryptosporidium, p. 31-49. In J. P. Dubey, C. A. Speer, and R. Fayer (ed.), Cryptosporidiosis of man and animals - 1990. CRC Press, Boston, Mass.
4. Current, W. L., and L. S. Garcia. 1991. Cryptosporidiosis. Clin. Microbiol. Rev. 4:325-358.
5. Davis, L. J., R. Soave, R. E. Dudley, J. W. Fessel, S. Faulkner, and J. P. Mamakos. 1996. Nitazoxanide (NTZ) for AIDS-related cryptosporidial diarrhea (CD): an open-label safety, efficacy and pharmacokinetic study, abstr. LM50, p. 289. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Doumbo, O., J. F. Rossignol, E. Pichard, et al. 1997. Nitazoxanide in treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56:637-639.
7. DuPont, H. L., C. L. Chappel, C. R. Sterling, P. O. Okhuysen, J. B. Rose, and W. Jakubowski. 1995. The infectivity of Cryptosporidium parvum in healthy volunteers. N. Engl. J. Med. 332:855-859.
8. Fayer, R., C. Andrews, B. L. P. Ungar, and B. L. Blagburn. 1989. Efficacy of hyperimmune bovine colostrum for prophylaxis of cryptosporidiosis in neonatal calves. J. Parasitol. 75:393-397.
9. Fayer, R., A. Guidry, and B. L. Blagburn. 1990. Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice. Infect. Immun. 58:2962-2965.
10. Griffiths, J. K. 1998. Human cryptosporidiosis: epidemiology, transmission, clinical disease, treatment and diagnosis. Adv. Parasitol. 40:30-87.
11. Mead, J. R., X. You, J. E. Pharr, Y. Belenkaya, M. J. Arrowood, M. T. Fallon, and R. F. Schinazi. 1995. Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis. Antimicrob. Agents Chemother. 39:854-858.
12. O'Donoghue, P. J. 1995. Cryptosporidium and cryptosporidiosis in man and animals. Int. J. Parasitol. 25:139-195.
13. Rehg, J. E., M. L. Hancock, and D. B. Woodmansee. 1988. Characterization of a dexamethasone-treated rat model of cryptosporidial infection. J. Infect. Dis. 158:1406-1407.
14. Rohlman, V. C., T. L. Kuhls, D. A. Mosier, D. L. Crawford, D. R. Hawkins, and V. L. Abrams. 1993. Therapy with atovaquone for Cryptosporidium parvum infection in neonatal severe combined immunodeficiency mice. J. Infect. Dis. 168:258-260.
15. Theodos, C. M., K. L. Sullivan, J. K. Griffiths, and S. Tzipori. 1997. Profiles of healing and nonhealing Cryptosporidium parvum infection in C57BL/6 mice with functional B and T lymphocytes: the extent of gamma interferon modulation determines the outcome of infection. Infect. Immun. 65:4761-4769.
16. Tzipori, S., I. Campbell, and T. Angus. 1982. The therapeutic effect of 16 antimicrobial agents on Cryptosporidium infection in mice. Aust. J. Exp. Biol. Med. Sci. 60:187-190.
17. Tzipori, S., W. Rand, J. Griffiths, G. Widmer, and J. Crabb. 1994. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin. Diagn. Lab. Immunol. 1:450-463.
18. Tzipori, S., W. Rand, and C. Theodos. 1995. Evaluation of a two-phase scid mouse model preconditioned with anti-interferon-γ monoclonal antibody for drug testing against Cryptosporidium parvum. J. Infect. Dis. 172:1160-1164.
19. Tzipori, S. 1998. Cryptosporidium parvum: laboratory investigations and chemotherapy. Adv. Parasitol. 40:188-221.
20. White, A. C., C. L. Chappell, C. S. Hayat, K. T. Kimball, T. P. Flanigan, and R. W. Goodgame. 1994. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J. Infect. Dis. 170:419-424.
21. Woods, K. M., M. V. Nesterenko, and S. J. Upton. 1996. Efficacy of 101 antimicrobials and other agents in the development of Cryptosporidium parvum in vitro. Ann. Trop. Med. Parasitol. 60:603-615.
22. Yang, S., and M. C. Healey. 1993. The immunosuppressive effects of dexamethasone administered in drinking water to C57BL/6N mice infected with Cryptosporidium parvum. J. Parasitol. 79:626-630.